Deep Tech Startups

Calycia Bioscience is a biotechnology company developing engineered macrophage cell therapies delivered locally into the brain to target aggressive solid tumors of the central nervous system. Its pipeline focuses on glioblastoma and melanoma brain metastasis within CNS oncology.

1 investor

Cambium develops high-performance advanced materials using AI-driven molecular design and agile domestic manufacturing for extreme-condition applications across aerospace, space, industrial, and defense sectors. The company provides thermal protection systems, structural materials, and specialized protection solutions that are stronger, lighter, and more resilient than conventional alternatives.

1 investor

Cambrian Works builds networking and connectivity infrastructure for satellite communications and space operations, including the GigRouter, a space-ready router and edge-computing device with onboard AI/ML processing. Its products support autonomous data management across hybrid space networks and link systems on Earth and in orbit.

1 investor

Cambrian Vision augments industrial robot arms with computer vision and AI-powered perception capabilities for tasks like bin picking, assembly, and cable handling. The platform includes synthetic data generation, path planning, simulation, and APIs for integration with major robot brands.

1 investor

Cambridge Nucleomics develops a single-molecule RNA counting "nanoarray" assay based on solid-state nanopore and DNA nanotechnology for diagnostic testing. The company applies its technology to RNA biology and microbiology-based diagnostics.

1 investor

CDT is a research and innovation centre focused on the conception, development, and testing of advanced materials, with applications spanning electronics, communications, green energy, and life sciences. It operates as the European Research and Innovation Centre of Sumitomo Chemical.

1 investor

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

1 investor

Canadian Strategic Missions Corporation (CSMC) develops dual-use space and defence technologies through two subsidiaries: CSMC Nuclear, which builds portable micro-nuclear reactors (LEUNR) for remote environments, and CSMC Labs, an R&D division commercializing deep-tech in quantum, robotics, nano-materials, and space systems. Its nuclear reactors target Canadian defence, Indigenous communities, and space exploration.

1 investor

Cantoni Therapeutics is a biotech company developing small molecule bisubstrate inhibitors of the enzyme nicotinamide N-methyltransferase (NNMT) as a treatment for obesity and its cardiometabolic complications such as type 2 diabetes and cardiovascular disease. Its inhibitor portfolio targets both the SAM and NA binding pockets of NNMT, aiming to offer an alternative to appetite-reducing anti-obesity medications.

1 investor

Cape Haven Bio is a venture creation firm focused on translating early-stage academic discoveries into commercially viable biotech companies developing therapeutics. The firm provides strategic planning, lab infrastructure, seed capital, and consulting resources to support the progression from research to investable business.

1 investor

NVentures is NVIDIA's venture capital arm, making strategic investments in technology companies working on AI infrastructure, robotics, digital biology, applied AI, and frontier compute. It builds long-term partnerships with founding teams and provides access to NVIDIA's technical teams, platform integrations, and go-to-market support.

1 investor

Capital 2B is a venture capital firm that invests in deep-tech and IP-led startups from pre-seed to Series A, writing first cheques of $200k–$3M, often as the first institutional investor. It focuses on companies at the intersection of computation, programmable biology, and advanced materials.

1 investor

Capoom provides 3D modeling, 3D scanning, and synthetic data solutions for AI training, simulations, and digital twins across various industries.

1 investor

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.

1 investor

Capuchin is an AI-powered enterprise search and knowledge management platform designed for engineering organizations that work with hardware, antennas, RF systems, optics, robotics, and similar technical products. The system operates entirely on-premise, indexing product data from PDM/PLM systems, ERPs, and collaboration tools while maintaining ITAR and CMMC compliance for defense and government-facing engineering teams.

1 investor

CapyBio provides tools to measure how closely cells match a target identity and to improve them, helping scientists and biopharma teams reduce failure in drug discovery, build stronger disease models, and advance cell-based therapies. The company applies cell biology and computational methods to cell identity for research, testing, and regenerative medicine.

1 investor

Carbo Energy builds hybrid non-aqueous redox flow batteries for grid-scale energy storage, designed to complement renewable energy sources with a 40-year lifespan, zero fire risk, and degradation of 0.2% annually. The company serves utilities, datacenters, mining operations, and renewable energy farms across multiple markets including energy trading, backup power, and off-grid operations.

1 investor

Carbon Cell is a team of designers, engineers, and scientists developing sustainable materials aimed at reducing plastic use and carbon emissions. The company operates in the sustainable materials and climate space.

1 investor

Carbon Clean Energy develops carbon conversion technology that transforms CO2 into chemicals, materials, and fuels using an artificial photosynthesis approach powered by renewable energy. The company serves industrial manufacturers and enterprises seeking decarbonization solutions and carbon-neutral product alternatives.

1 investor

Carbonext produces high-quality 3D graphene using a scalable chemical process that substitutes graphite with biomass and industrial waste materials. The company targets commercial applications by reducing graphene production costs and enabling bulk supply at scale.

1 investor

Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.

1 investor

Carroucell develops microcarrier technology for cell and gene therapy applications, enabling cost-effective bioproduction and cell amplification. The company serves the healthcare and biomanufacturing industries with sol-gel based microcarrier solutions.

1 investor

Carterra develops surface plasmon resonance (SPR) platforms for high-throughput biomolecular interaction analysis. The systems are designed for drug discovery, antibody development, and screening applications in research and biotech organizations.

1 investor

Carus Bio develops next-generation in vivo CAR-T therapeutics using an mRNA delivery platform technology for cell and gene therapy. The company focuses on treatments for patients in the biotech and cell-gene therapy field.

1 investor